BioRx Announces Health Outcomes Reporting Program for Primary Immune Deficiencies
CINCINNATI, Ohio (April 16, 2014) – BioRx, a national specialty pharmacy provider, announced today the expansion of its BioFeedback reporting program. Originally launched in September 2013 for autoimmune-related neuromuscular disorders, the program now offers a reporting package designed specifically for primary immune deficiency disease (PIDD). Similar to autoimmune disorders, BioFeedback for immune deficiencies tracks individual health outcomes that help measure a patient’s response to treatment with immunoglobulin (IgG) therapy.
Primary immune deficiencies consist of more than 150 disease variants that impair the body’s immunity against infection. Together, they represent the most common use of IgG treatment. IgG therapy – the infusion of replacement antibodies – is the preferred treatment for some of the most common forms of PIDD.
“PIDD is a lifelong disease that carries ongoing risks to a patient’s health,” said Eric Hill, co-founder of BioRx. “Today, almost half of PIDD patients are treated at home – either by themselves or with the help of an infusion nurse. In that case, physicians are often in the dark about how their patients are doing. Our BioFeedback report allows physicians to make general health and treatment observations that can alert them to potential warning signs – be it non-compliance, recurring infections, or self-reported feelings of weakness or fatigue.”
Through its routine contact with patients – via telephone and in-home nursing visits – BioRx is able to monitor an individual’s IgG treatment progress over time. Each month, a BioRx consumer advocate contacts patients to review their interim health outcomes and current supply needs. (A consumer advocate at BioRx is a trained customer service representative who either shares the diagnosis of a patient or cares for someone who does.) BioRx then combines this self-reported patient information with its pharmacy and clinical records to generate a graphical portrait of a patient’s long-term response to therapy. This includes IgG dispense history, hospital stays and ER visits, infections, antibiotic treatments, and quality of life. On a quarterly basis, BioRx distributes the trended results to a patient’s prescribing physician, in print or electronic format.
In developing the BioFeedback program, BioRx consulted with a number of medical thought leaders and practicing immunologists experienced with PIDD. Hill says their ongoing input will continue to enhance and improve the program. “What we’re hearing is that there’s a real hunger to know how patients are responding to treatment,” said Hill. “We also know that insurance companies are requesting more evidence from physicians to support the ongoing use of IgG therapy. And that poses a long list of areas where we can help.”
BioRx continues to develop and expand the uses of its BioFeedback reporting platform, including therapeutic areas beyond immunoglobulin. For more information or questions about the BioFeedback program, call 866.44.BIORX (866.442.4679), email email@example.com, or visit www.biorximmunotherapy.com.
Download News Release (PDF)
About Immunoglobulin Therapy
Immunoglobulin is a sterilized pharmaceutical product prepared from the pooled plasma of tens of thousands of screened blood donors. Intravenous immunoglobulin (IVIg) is the infusion of immunoglobulin into a vein. Subcutaneous immunoglobulin (SCIg) is the infusion of immunoglobulin into tissue under the skin.
Immunoglobulins are antibodies found in human blood plasma. In the simplest terms, immunoglobulin therapy is the infusion of human antibodies. Antibodies are important to the body’s defense against foreign substances such as viruses and other disease-causing pathogens. The antibodies are collected from pooled plasma that has been carefully screened and tested for safety. Immunoglobulin product manufacturers take plasma from large numbers of donors and extract the antibodies from the “pool,” then concentrate, clean and preserve the antibodies into a medically useful pharmaceutical product.
Immunoglobulin is typically used for patients with primary immune deficiency diseases, autoimmune neuromuscular disorders, and certain types of leukemia and transplants. The number of diseases treated by this unique therapy is continually growing, but is estimated to exceed 150.
Based in Cincinnati, Ohio, BioRx is one of the nation’s fastest growing providers of specialty pharmaceuticals and infusion services, delivering highly customized care for patients with certain rare and chronic diseases. In addition to serving patients with primary immune deficiencies, BioRx offers pharmacy, nursing and education services to patients with hemophilia, hereditary angioedema, autoimmune disorders, and alpha-1 antitrypsin deficiency. The company’s clinical staff reaches patients and physicians in all 50 states. To learn more about BioRx and its products and services, visit www.biorx.com.